Leerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating on Merck (NYSE: MRK).The analyst comments "Bottom Line: Gardasil remained ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE